Valence8 US’s Kezar Life Sciences KZR Stock Holding History

Valence8 US’s Portfolio KZR Stock Details KZR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,114	Closed	-$16.3K	–	41
2024 Q3	$16.3K	Buy	+2,114	New	+$12.8K	0.01%	62

Other funds holding KZR

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Acadian Asset Management

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Valence8 US's KZR Position: Q4 2024 in Review

Valence8 US sold out of Kezar Life Sciences (KZR) in Q4 2024, closing a stake of 2,114 shares — an estimated $16.3K sold.

Valence8 US first reported a position in KZR in Q3 2024 and held it in 1 quarter. The position peaked at $16.3K in Q3 2024. 43 funds tracked by Wall St. Rank hold KZR as of Q4 2024.

Valence8 US reported no remaining Kezar Life Sciences position as of Q4 2024 after selling out during the quarter.
Valence8 US sold 2,114 Kezar Life Sciences shares in Q4 2024, an estimated $16.3K.
Valence8 US first reported a position in Kezar Life Sciences in Q3 2024 and held it in 1 quarter.
Valence8 US's Kezar Life Sciences position peaked at $16.3K in Q3 2024.
43 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q4 2024.

Based on Valence8 US's 13F filing for Q4 2024, filed 12 Feb 2025.